|last updated on: August 25, 2015||
|Homepage > Centers > Stanford University Proteomics Center|
Stanford University Proteomics Center
Director: Garry Nolan, PhD
Pulmonary arterial hypertension (PAH) is a devastating disease that affects over 5,000 Americans. By the time patients present with even vague and insidious symptoms such as fatigue and dyspnea, they have much higher PA pressures, which eventually result in right heart failure.
Our Center's approach is a highly interdisciplinary effort to explore and converge results from different, innovative platform technologies that analyze intracellular and secreted proteins related to pulmonary arterial hypertension (PAH) with a continuing development of relational “systems” approaches that allow the integration, comparison and correlation of different datasets generated by diverse technologies developed at the Center. A strong focus is on developing a picture of immune processes and inflammation that both describe the disease and stimulate innovation in patient treatment strategies focused on the true biology underlying the clinical manifestation. The approaches employed are cutting-edge variations of "familiar" technologies that we expect can move to mainstream clinical practice within a short period of time.
|National Heart, Lung, and Blood Institute||National Institutes of Health||Department of Health and Human Services|